59 results
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
which bring the reputation of the PLC or any Group Company into material disrepute; (v) any act or omission by Executive aiding or abetting a competitor
8-K
EX-10.4
n0iv44 4u6
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
a1gi878c17
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
qs7bgk8m5k7mg
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
424B3
iioft9th1 crt9mkt
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
ydfokq0xcpjglcy4 857
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
385hqe4oi3xh
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-10.01
4h4p8s h9v120906
26 Jan 22
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
8:05am